Sivaraman Padmapriya, Cohen Stanley B
Department of Internal Medicine, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd, Dallas, TX 75390, USA; Division of Rheumatology, Presbyterian Hospital, 8200 Walnut Hill Ln, Dallas, TX 75231, USA; Metroplex Clinical Research Center, 8144 Walnut Hill Ln, #800, Dallas, TX 75231, USA.
Department of Internal Medicine, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd, Dallas, TX 75390, USA; Division of Rheumatology, Presbyterian Hospital, 8200 Walnut Hill Ln, Dallas, TX 75231, USA; Metroplex Clinical Research Center, 8144 Walnut Hill Ln, #800, Dallas, TX 75231, USA.
Rheum Dis Clin North Am. 2017 Feb;43(1):79-93. doi: 10.1016/j.rdc.2016.09.008.
The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population. The incidence of all malignancy (excluding NMSC) was similar in tofacitinib users compared with the general population. The rates of overall and site-specific malignancies in patients with RA treated with tofacitinib are similar to what is expected in the RA population and not different from disease-modifying antirheumatic drugs and biologics.
使用抗肿瘤坏死因子等生物制剂和口服 Janus 激酶抑制剂彻底改变了类风湿关节炎（RA）的治疗方法。与普通人群相比，RA 患者患淋巴瘤、肺癌和非黑色素瘤皮肤癌（NMSC）等恶性肿瘤的风险更高。与普通人群相比，托法替布使用者的所有恶性肿瘤（不包括 NMSC）发病率相似。接受托法替布治疗的 RA 患者的总体和特定部位恶性肿瘤发生率与 RA 人群的预期发生率相似，与改善病情抗风湿药物和生物制剂无差异。
